Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.

Erwan Bezard, Sandra Dovero, Bernard Bioulac, Christian Gross
Experimental Neurology. 1997-11-01; 148(1): 288-292
DOI: 10.1006/exnr.1997.6648

PubMed
Read on PubMed



1. Exp Neurol. 1997 Nov;148(1):288-92.

Effects of different schedules of MPTP administration on dopaminergic
neurodegeneration in mice.

Bezard E(1), Dovero S, Bioulac B, Gross C.

Author information:
(1)Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II,
France.

Although a valuable 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal
model of human Parkinson’s disease has been developed, our knowledge of the
course of nigral degeneration remains fragmentary. Experimental factors which
could possibly influence the destructive process must be taken into account. To
evaluate the impact of experimental design, we compared the effects of different
schedules of injection of the same cumulative dose of MPTP, in mice, by measuring
tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta.
Massive injection of the total dose over 1 day (4 injections of 20 mg/kg)
destroyed more dopaminergic neurons than did the long-term daily injections of a
lower dose of MPTP (20 injections of 4 mg/kg). This suggests that different
schedules of administration of MPTP might induce different mechanisms of neuronal
death. These mechanisms need to be better understood if chronic models of
intoxication that replicate the evolution of human Parkinson’s disease more
precisely are to be developed.

DOI: 10.1006/exnr.1997.6648
PMID: 9398471 [Indexed for MEDLINE]

Know more about